Cardunolizumab
Phase 2Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Vulvar and Vaginal Cancer
Conditions
Vulvar and Vaginal Cancer
Trial Timeline
Mar 22, 2024 → Mar 22, 2027
NCT ID
NCT06292689About Cardunolizumab
Cardunolizumab is a phase 2 stage product being developed by Innovent Biologics for Vulvar and Vaginal Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06292689. Target conditions include Vulvar and Vaginal Cancer.
What happened to similar drugs?
0 of 2 similar drugs in Vulvar and Vaginal Cancer were approved
Approved (0) Terminated (1) Active (1)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06292689 | Phase 2 | Recruiting |
Competing Products
7 competing products in Vulvar and Vaginal Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Tacrolimus cream + Clobetasol cream | Astellas Pharma | Phase 2 | 35 |
| Estradiol | Sun Pharmaceutical | Phase 3 | 32 |
| Estradiol Vaginal Tablets 10 mcg (Glenmark) + Vagifem® (Estradiol Vaginal Tablets) 10 mcg (Novo Nordisk) + Placebo of Estradiol Vaginal Tablets 10 mcg (Glenmark) | Glenmark Pharmaceuticals | Phase 3 | 40 |
| Cisplatin + Pembrolizumab | Merck | Phase 2 | 39 |
| AK104 + AK104+ Paclitaxel+Cisplatin or Carboplatin | Akeso | Phase 2 | 42 |
| AVA6103 | Avacta Group | Phase 1 | 26 |
| VGX-3100 + Imiquimod 5% Cream | Inovio Pharmaceuticals | Phase 2 | 25 |